Clarity Pharmaceuticals Ltd
CU6
Rank in Stocks
#13055
Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company,... Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, engages in research and development of radiopharmaceuticals products for oncology in Australia and the United States. The companyโs lead product is SAR-bisPSMA, a theranostic radiopharmaceutical for the treatment of Prostate Specific Membrane Antigen (PSMA) cancer. It also develops SAR-Bombesin, a pan cancer theranostic radiopharmaceutical to treat prostate, breast, ovarian, urinary, small cell lung cancer, as well as glioblastoma and gastrointestinal stromal tumours; and SARTATE, a theranostic radiopharmaceutical for the treatment of somatostatin receptor 2 (SSTR2) cancer. The company was incorporated in 2010 and is based in Sydney, Australia.
Share Price
$1.12
Last synced: 2026-11-10
Market Cap
$418.35M
Change (1 day)
2.21%
Change (1 year)
-62.81%
Country
Stock data: Financial Modeling PrepยทUpdated ยทNot investment adviceยทHow we calculate this
Trade Clarity Pharmaceuticals Ltd (CU6)
Category
Healthcare
EPS for Clarity Pharmaceuticals Ltd (CU6)
EPS as of June 2026 TTM: $-0.20
According to Clarity Pharmaceuticals Ltd's latest financial reports, its current EPS (TTM) is $-0.20. At the end of 2025 the company had an EPS of $-0.13, a decrease compared to its 2024 EPS of $-0.10.
EPS history for Clarity Pharmaceuticals Ltd from 2018 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-0.20 | 57.38% |
| 2025 | $-0.13 | 31.44% |
| 2024 | $-0.10 | 59.05% |
| 2023 | $-0.06 | -4.40% |
| 2022 | $-0.07 | 121.14% |
| 2021 | $-0.03 | 59.36% |
| 2020 | $-0.02 | 87.00% |
| 2019 | $-0.01 | 100.00% |
| 2018 | $-0.01 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $8.45 | -4,230.01% |
IE
|
|
| $0.21 | -201.91% |
CN
|
|
| $19.69 | -9,723.07% |
CH
|
|
| $4.34 | -2,220.23% |
CH
|
|
| $0.13 | -161.58% |
CN
|
Questions about Clarity Pharmaceuticals Ltd's earnings per share (EPS)
What is Clarity Pharmaceuticals Ltd's earnings per share (EPS)?
Clarity Pharmaceuticals Ltd's earnings per share (EPS) over the last twelve months is $-0.20, as of Jun 2026.
What was Clarity Pharmaceuticals Ltd's earnings per share (EPS) in 2025?
In 2025, Clarity Pharmaceuticals Ltd's earnings per share (EPS) was $-0.13, compared with $-0.10 in 2024.
How has Clarity Pharmaceuticals Ltd's earnings per share (EPS) changed since 2020?
From 2020 to 2025, Clarity Pharmaceuticals Ltd's earnings per share (EPS) was highest in 2020 ($-0.02) and lowest in 2025 ($-0.13).
How does Clarity Pharmaceuticals Ltd's earnings per share (EPS) compare with similar companies?
Clarity Pharmaceuticals Ltd's earnings per share (EPS) ($-0.20) is lower than that of all 5 similar companies listed above. The highest among them is Ypsomed Holding AG, with $19.69.